Safety and Stability of Antibody-Dye Conjugate in Optical Molecular Imaging

Autor: Shrey Kapoor, George A. Poultsides, Yu-Jin Lee, Eben L. Rosenthal, Stefania U. Chirita, Georgina Juniper, Anthony R. Welch, Gordon Li, Roan C Raymundo, Jacqueline Pei, Trevor Broadt, Nynke S. van den Berg, A. Dimitrios Colevas, Kurt R. Zinn, Naoki Nisho, Quan Zhou, Grace Yi, Natalie S. Lui, Guolan Lu, Giri Krishnan
Rok vydání: 2020
Předmět:
Zdroj: Mol Imaging Biol
ISSN: 1860-2002
1536-1632
Popis: PURPOSE: The development of molecularly targeted tracers is likely to improve the accuracy of diagnostic, screening, and therapeutic tools. Despite the many therapeutic antibodies that are FDA-approved with known toxicity, only a limited number of antibody-dye conjugates have been introduced to the clinic. Thorough evaluation of the safety, stability and pharmacokinetics of antibody conjugates in the clinical setting compared to their parental components could accelerate the clinical approval of antibodies as agents for molecular imaging. Here we investigate the safety and stability of a near-infrared fluorescent dye (IRDye800CW) conjugated panitumumab, an approved therapeutic antibody, and report on the product stability, pharmacokinetics, adverse events, and QTc interval changes in patients. PROCEDURES: Panitumumab-IRDye800CW was made under good manufacturing practice (GMP) conditions in a single batch on March 26, 2014 and then evaluated over 4.5 years at 0, 3, and 6 months, and then at 6-month intervals thereafter. We conducted early phase trials in head and neck, lung, pancreas and brain cancers with panitumumab-IRDye800CW. Eighty-one patients scheduled to undergo standard of care surgery were infused with doses between 0.06mg/kg to 2.83mg/kg of antibody. Patient ECGs, blood samples, and adverse events were collected over 30-days post-infusion for analysis. RESULTS: 81 patients underwent infusion of the study drug at a range of doses. Six patients (7.4%) experienced an adverse event that was considered potentially related to the drug. The most common event was a prolonged QTc interval which occurred in three patients (3.7%). Panitumumab-IRDye800CW had two OOS results at 42 and 54 months, while meeting all other stability testing criteria. CONCLUSIONS: Panitumumab-IRDye800CW was safe and stable to administer over a 54-month window with a low rate of adverse events (7.4%) which is consistent with the rate associated with panitumumab alone. This data supports re-purposing therapeutic antibodies as diagnostic imaging agents with limited preclinical toxicology studies.
Databáze: OpenAIRE
Externí odkaz: